Rahul Banerjee: Dexamethasone 40mg weekly in Multiple Myeloma induction
Rahul Banerjee shared his recent article on X:
“Grateful to Blood Journal, co-authors, and SWOG Cancer Research Network for making this down with dex piece possible!
Dexamethasone 40mg weekly in Multiple Myeloma induction: Not practical even for trial-enrolled patients. Does not improve PFS vs dex Twitter once I’m back from IMS24!”
Urvi Shah, Oncologist, Memorial Sloan Kettering Cancer Center reshared the post, adding:
“Such important data and helpful for patients! Sometimes less is more or equal too!
Congratulations Rahul Banerjee!”
Authors: Rahul BanerjeeRachael SextonAndrew J. CowanAaron S. RosenbergSikander AilawadhiS. Vincent RajkumarShaji K KumarAngela DispenzieriSagar LonialBrian G.M. DuriePaul G. RichardsonSaad Z UsmaniAntje Hoering and Robert Z Orlowski.
Source: Urvi Shah/X and Rahul Banerjee/X
Rahul Banerjee is an assistant professor at Fred Hutchinson Cancer Center at the University of Washington. He completed his residency from the University of Pennsylvania health system. He completed his fellowship in haematology and oncology from University of California, San Francisco. He has authored over 70-peer reviewed publications. His clinical interests include multiple myeloma.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023